Results 151 to 160 of about 16,542 (247)
Clinical &Experimental Allergy, Volume 55, Issue 3, Page 253-255, March 2025.
Robert Greig +4 more
wiley +1 more source
Summary Background and objectives Trust in therapy impacts adherence and satisfaction in chronic inflammatory skin diseases, including atopic dermatitis (AD) and psoriasis (PSO). This study assessed and compared trust in skincare and topical therapies and explored influencing factors among AD and PSO patients.
Svenja Royeck +9 more
wiley +1 more source
Long-Term Ocular Outcomes of Dupilumab in Atopic Dermatitis: Results From the BioDay Registry. [PDF]
Veldhuis N +12 more
europepmc +1 more source
Clinical &Experimental Allergy, Volume 55, Issue 3, Page 260-263, March 2025.
Celeste M. Boesjes +7 more
wiley +1 more source
Nineteen nail dystrophy in an atopic background responsive to dupilumab: a case report. [PDF]
Zang Y +5 more
europepmc +1 more source
Clinical &Experimental Allergy, Volume 55, Issue 3, Page 264-266, March 2025.
Kirsten E. Stewart +3 more
wiley +1 more source
Dupilumab Alleviates Pulmonary Fibrosis by Interrupting Profibrotic Macrophage-Fibroblast Crosstalk and IL4R/JAK/STAT Signaling. [PDF]
Chen Q +9 more
europepmc +1 more source
Cardiovascular Outcomes With Dupilumab Versus Omalizumab in Severe Asthma
Clinical &Experimental Allergy, EarlyView.
Po‐Cheng Shih +2 more
wiley +1 more source
Cutaneous lymphomas – an update
Primary cutaneous lymphomas and lymphoproliferative disorders are defined by integrated clinical, histopathological, immunophenotypic and genetic features as diagnostic criteria also in the 5th edition of the WHO classification of haematolymphoid tumors.
Werner Kempf, Christina Mitteldorf
wiley +1 more source
Precision targeting of type 2 inflammation in COPD: identifying candidates for dupilumab therapy. [PDF]
Zhong K, Lv K, Liang Q.
europepmc +1 more source

